These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32127466)

  • 1. Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.
    Strickler JH; LoRusso P; Salgia R; Kang YK; Yen CJ; Lin CC; Ansell P; Motwani M; Wong S; Yue H; Wang L; Reilly E; Afar D; Naumovski L; Ramanathan RK
    Mol Cancer Ther; 2020 May; 19(5):1210-1217. PubMed ID: 32127466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
    J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors.
    Fujiwara Y; Kenmotsu H; Yamamoto N; Shimizu T; Yonemori K; Ocampo C; Parikh A; Okubo S; Fukasawa K; Murakami H
    Cancer Med; 2021 Apr; 10(7):2350-2358. PubMed ID: 33675179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
    Camidge DR; Morgensztern D; Heist RS; Barve M; Vokes E; Goldman JW; Hong DS; Bauer TM; Strickler JH; Angevin E; Motwani M; Parikh A; Sun Z; Bach BA; Wu J; Komarnitsky PB; Kelly K
    Clin Cancer Res; 2021 Nov; 27(21):5781-5792. PubMed ID: 34426443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
    Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
    J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
    Ferrarotto R; Eckhardt G; Patnaik A; LoRusso P; Faoro L; Heymach JV; Kapoun AM; Xu L; Munster P
    Ann Oncol; 2018 Jul; 29(7):1561-1568. PubMed ID: 29726923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
    Angevin E; Spitaleri G; Rodon J; Dotti K; Isambert N; Salvagni S; Moreno V; Assadourian S; Gomez C; Harnois M; Hollebecque A; Azaro A; Hervieu A; Rihawi K; De Marinis F
    Eur J Cancer; 2017 Dec; 87():131-139. PubMed ID: 29145039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
    Jimeno A; Moore KN; Gordon M; Chugh R; Diamond JR; Aljumaily R; Mendelson D; Kapoun AM; Xu L; Stagg R; Smith DC
    Invest New Drugs; 2019 Jun; 37(3):461-472. PubMed ID: 30229512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
    Angevin E; Tabernero J; Elez E; Cohen SJ; Bahleda R; van Laethem JL; Ottensmeier C; Lopez-Martin JA; Clive S; Joly F; Ray-Coquard I; Dirix L; Machiels JP; Steven N; Reddy M; Hall B; Puchalski TA; Bandekar R; van de Velde H; Tromp B; Vermeulen J; Kurzrock R
    Clin Cancer Res; 2014 Apr; 20(8):2192-204. PubMed ID: 24563479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
    Waqar SN; Redman MW; Arnold SM; Hirsch FR; Mack PC; Schwartz LH; Gandara DR; Stinchcombe TE; Leighl NB; Ramalingam SS; Tanna SH; Raddin RS; Minichiello K; Bradley JD; Kelly K; Herbst RS; Papadimitrakopoulou VA
    Clin Lung Cancer; 2021 May; 22(3):170-177. PubMed ID: 33221175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
    Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
    Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.
    Gordon MS; Nemunaitis J; Barve M; Wainberg ZA; Hamilton EP; Ramanathan RK; Sledge GW; Yue H; Morgan-Lappe SE; Blaney M; Kasichayanula S; Motwani M; Wang L; Naumovski L; Strickler JH
    Mol Cancer Ther; 2021 Oct; 20(10):1988-1995. PubMed ID: 34315767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 study of ABT-806 in subjects with advanced solid tumors.
    Cleary JM; Reardon DA; Azad N; Gandhi L; Shapiro GI; Chaves J; Pedersen M; Ansell P; Ames W; Xiong H; Munasinghe W; Dudley M; Reilly EB; Holen K; Humerickhouse R
    Invest New Drugs; 2015 Jun; 33(3):671-8. PubMed ID: 25895099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer.
    Lee J; Kim ST; Park S; Lee S; Park SH; Park JO; Lim HY; Ahn H; Bok H; Kim KM; Ahn MJ; Kang WK; Park YS
    Clin Colorectal Cancer; 2018 Jun; 17(2):140-146. PubMed ID: 29551559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
    Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
    Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
    Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
    Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.
    Bang YJ; Su WC; Schuler M; Nam DH; Lim WT; Bauer TM; Azaro A; Poon RTP; Hong D; Lin CC; Akimov M; Ghebremariam S; Zhao S; Giovannini M; Ma B
    Cancer Sci; 2020 Feb; 111(2):536-547. PubMed ID: 31778267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.